A recent study showed that targeting NLRP3 inflammasome by gene knockout or selective inhibitor MCC950 ameliorated overactive inflammatory response and pathology of lung in mice models with SARS-CoV-2 infection,158 as does in the previous study of influenza A.159 A multicenter, randomized, controlled phase II trial of DFV890 (a selective NLRP3 inflammasome inhibitor) treatment for COVID-19 with pneumonia and impaired respiratory function exhibited negative results (NCT04382053). Here, NLRP3 is linked to COVID-19.